FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114832110> ?p ?o ?g. }

• W2114832110 endingPage "881" @default.
• W2114832110 startingPage "876" @default.
• W2114832110 abstract "Herpes zoster is the most common infection in patients treated with bortezomib-containing regimens for multiple myeloma. Some clinical trials have reported on the use of acyclovir prophylaxis to decrease the incidence of herpes zoster. However, the appropriate acyclovir dose and duration of prophylaxis remain unclear. The primary objective of this study was to evaluate the efficacy of continuous oral 200 mg/day acyclovir prophylaxis and the secondary objective was to determine the risk factors for developing herpes zoster.We collected medical information from consecutive patients who received bortezomib with or without acyclovir prophylaxis for relapsed or refractory multiple myeloma at our hospital and retrospectively analyzed the efficacy of acyclovir prophylaxis and the parameters for predicting the risk factors for developing herpes zoster. The definition of acyclovir prophylaxis was oral continuous administration of 200 mg of once daily, without cessation, during the entire period of bortezomib treatment.Six of the 33 patients in the study developed herpes zoster during bortezomib treatment. No varicella-zoster virus reactivation was observed in the 19 patients in the acyclovir prophylaxis group. The incidence of herpes zoster was significantly higher in the group that did not receive acyclovir prophylaxis (43%, 6 of 14 patients) than in the group that did (0%, 0 of 19; P = 0.003). The predictive factors for varicella-zoster virus reactivation were male sex (P = 0.035) and the use of acyclovir (P = 0.003).Continuous prophylaxis by oral 200 mg/day acyclovir in multiple myeloma patients receiving bortezomib treatment is effective and sufficient in preventing herpes zoster." @default.
• W2114832110 created "2016-06-24" @default.
• W2114832110 creator A5034295941 @default.
• W2114832110 creator A5048075263 @default.
• W2114832110 creator A5077833764 @default.
• W2114832110 creator A5082772073 @default.
• W2114832110 date "2011-05-25" @default.
• W2114832110 modified "2023-10-15" @default.
• W2114832110 title "Efficacy of Continuous, Daily, Oral, Ultra-low-dose 200 mg Acyclovir to Prevent Herpes Zoster Events Among Bortezomib-treated Patients: A Report From Retrospective Study" @default.
• W2114832110 cites W1516702206 @default.
• W2114832110 cites W1971793902 @default.
• W2114832110 cites W1977314954 @default.
• W2114832110 cites W1978468500 @default.
• W2114832110 cites W1998244873 @default.
• W2114832110 cites W2000452027 @default.
• W2114832110 cites W2007730238 @default.
• W2114832110 cites W2020358318 @default.
• W2114832110 cites W2023954230 @default.
• W2114832110 cites W2027676299 @default.
• W2114832110 cites W2067155443 @default.
• W2114832110 cites W2107154392 @default.
• W2114832110 cites W2108235071 @default.
• W2114832110 cites W2122277484 @default.
• W2114832110 cites W2131140606 @default.
• W2114832110 cites W2133590829 @default.
• W2114832110 cites W2141169323 @default.
• W2114832110 cites W2146768400 @default.
• W2114832110 cites W2156748957 @default.
• W2114832110 cites W2159195400 @default.
• W2114832110 doi "https://doi.org/10.1093/jjco/hyr063" @default.
• W2114832110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21616919" @default.
• W2114832110 hasPublicationYear "2011" @default.
• W2114832110 type Work @default.
• W2114832110 sameAs 2114832110 @default.
• W2114832110 citedByCount "18" @default.
• W2114832110 countsByYear W21148321102012 @default.
• W2114832110 countsByYear W21148321102014 @default.
• W2114832110 countsByYear W21148321102015 @default.
• W2114832110 countsByYear W21148321102016 @default.
• W2114832110 countsByYear W21148321102017 @default.
• W2114832110 countsByYear W21148321102018 @default.
• W2114832110 countsByYear W21148321102019 @default.
• W2114832110 countsByYear W21148321102020 @default.
• W2114832110 countsByYear W21148321102022 @default.
• W2114832110 crossrefType "journal-article" @default.
• W2114832110 hasAuthorship W2114832110A5034295941 @default.
• W2114832110 hasAuthorship W2114832110A5048075263 @default.
• W2114832110 hasAuthorship W2114832110A5077833764 @default.
• W2114832110 hasAuthorship W2114832110A5082772073 @default.
• W2114832110 hasBestOaLocation W21148321101 @default.
• W2114832110 hasConcept C120665830 @default.
• W2114832110 hasConcept C121332964 @default.
• W2114832110 hasConcept C126322002 @default.
• W2114832110 hasConcept C141071460 @default.
• W2114832110 hasConcept C142424586 @default.
• W2114832110 hasConcept C167135981 @default.
• W2114832110 hasConcept C203014093 @default.
• W2114832110 hasConcept C2522874641 @default.
• W2114832110 hasConcept C2776159415 @default.
• W2114832110 hasConcept C2776364478 @default.
• W2114832110 hasConcept C2776409557 @default.
• W2114832110 hasConcept C2777478702 @default.
• W2114832110 hasConcept C2779450786 @default.
• W2114832110 hasConcept C2780727368 @default.
• W2114832110 hasConcept C535046627 @default.
• W2114832110 hasConcept C61511704 @default.
• W2114832110 hasConcept C71924100 @default.
• W2114832110 hasConcept C87355193 @default.
• W2114832110 hasConcept C90924648 @default.
• W2114832110 hasConceptScore W2114832110C120665830 @default.
• W2114832110 hasConceptScore W2114832110C121332964 @default.
• W2114832110 hasConceptScore W2114832110C126322002 @default.
• W2114832110 hasConceptScore W2114832110C141071460 @default.
• W2114832110 hasConceptScore W2114832110C142424586 @default.
• W2114832110 hasConceptScore W2114832110C167135981 @default.
• W2114832110 hasConceptScore W2114832110C203014093 @default.
• W2114832110 hasConceptScore W2114832110C2522874641 @default.
• W2114832110 hasConceptScore W2114832110C2776159415 @default.
• W2114832110 hasConceptScore W2114832110C2776364478 @default.
• W2114832110 hasConceptScore W2114832110C2776409557 @default.
• W2114832110 hasConceptScore W2114832110C2777478702 @default.
• W2114832110 hasConceptScore W2114832110C2779450786 @default.
• W2114832110 hasConceptScore W2114832110C2780727368 @default.
• W2114832110 hasConceptScore W2114832110C535046627 @default.
• W2114832110 hasConceptScore W2114832110C61511704 @default.
• W2114832110 hasConceptScore W2114832110C71924100 @default.
• W2114832110 hasConceptScore W2114832110C87355193 @default.
• W2114832110 hasConceptScore W2114832110C90924648 @default.
• W2114832110 hasIssue "7" @default.
• W2114832110 hasLocation W21148321101 @default.
• W2114832110 hasLocation W21148321102 @default.
• W2114832110 hasOpenAccess W2114832110 @default.
• W2114832110 hasPrimaryLocation W21148321101 @default.
• W2114832110 hasRelatedWork W1991948976 @default.
• W2114832110 hasRelatedWork W2027348595 @default.
• W2114832110 hasRelatedWork W2063424779 @default.
• W2114832110 hasRelatedWork W2104706142 @default.
• W2114832110 hasRelatedWork W2104965094 @default.

• next